主页 > 医学讨论 >
【medical-news】激光治疗并不能阻止早期AMD患者的
Researchers at Penn and other sites find no benefit of 35-year-old treatment
(Philadelphia, PA) - According to a study that appears in the November 2006 issue of the journal Ophthalmology, researchers at the University of Pennsylvania School of Medicine and 21 other clinical centers have found that low-intensity laser treatment - thought to be potentially beneficial in slowing or preventing the loss of vision from age-related macular degeneration (AMD) - is ineffective in preventing complications of AMD or vision loss. This is the major conclusion of the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT) -a research study supported by grants from the National Eye Institute (NEI) of the National Institutes of Health (NIH).
According to the NEI, AMD is a disease associated with aging that gradually destroys sharp, central vision. Central vision is needed for seeing objects clearly and for common daily tasks such as reading and driving. People with early AMD have drusen - yellow deposits under the retina. The presence of drusen is the first sign of early AMD, and eyes with large drusen are at an increased risk of progressing to advanced AMD, with accompanying loss of vision.
"For the past 35 years, ophthalmologists have wondered about the advisability of employing preventive laser treatment for patients with large drusen who are at a high risk for vision loss and AMD," said Stuart L. Fine, MD, CAPT chairman and chair, Penn's Department of Ophthalmology; Director, Scheie Eye Institute. "We found that laser treatment had neither a clinically significant beneficial nor harmful effect for these patients. There is no evidence from this trial to suggest that people with large drusen should seek preventive laser treatment."
This was the first large-scale, multicenter study to evaluate the efficacy and safety of this technique. The study followed 1,042 participants over the age of 50 (average age of 71) who had 10 or more large drusen and visual acuity of 20/40 or better in each eye. One eye of each participant was treated, while the other eye was observed throughout the five years of the trial. After five years, 20.5% of the treated eyes and 20.5% of the untreated eyes had lost three or more lines of visual acuity on a standard eye chart.
Currently, the only established way to decrease the risk of vision loss in people with large drusen is daily supplements of vitamins and minerals. The NEI-sponsored Age-Related Eye Diseases Study (AREDS) reported in 2001 that a formulation which includes anti-oxidant vitamins (beta-carotene, Vitamin C and Vitamin E) and appropriate doses of zinc and copper could reduce the relative risk of progression from early to late AMD by 25% and reduce the relative risk of vision loss by 19%. The NEI recently launched AREDS2 to see if a modified combination of vitamins, minerals, and fish oil can further slow the progression of vision loss for AMD. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 激光治疗并不能阻止早期AMD患者的视力丧失
（编者加）老年性黄斑变性又称年龄相关性黄斑变性（AMD），为黄斑区结构的衰老性改变。主要表现为视网膜色素上皮细胞对视细胞外节盘膜吞噬消化能力下降，结果使未被完全消化的盘膜残余小体潴留于基底部细胞原浆中，并向细胞外排出，沉积于Bruch膜，形成玻璃膜疣。由于黄斑部结构与功能上的特殊性，此种改变更为明显。玻璃膜疣也见于正常视力的老年人，但由此继发的种种病理改变后，则导致黄斑部变性发生。本病大多发生于45岁以上，其患病率随年龄增长而增高，是当前老年人致盲的重要疾病。
Laser treatment not effective in preventing vision loss for people with early AMD Researchers at Penn and other sites find no benefit of 35-year-old treatment(Philadelphia, PA) - According to a study that appears in the November 2006 issue of the journal Ophthalmology, researchers at the University of Pennsylvania School of Medicine and 21 other clinical centers have found that low-intensity laser treatment - thought to be potentially beneficial in slowing or preventing the loss of vision from age-related macular degeneration (AMD) - is ineffective in preventing complications of AMD or vision loss.
宾西法尼亚大学医学院以及其他21个临床机构的研究研究显示，低强度的激光治疗对早期老年性黄斑变性(,以下称AMD)患者预防失明没有疗效——报道刊登发表在2006年11月的《眼科杂志》上。宾西法尼亚大学及其他21个地区的研究者发现激光治疗对35岁左右的患者意义不大。在此之前人们都认为激光治疗AMD患者对阻止及预防失明是有效的，然而研究显示事实并非如此。
This is the major conclusion of the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT) -a research study supported by grants from the National Eye Institute (NEI) of the National Institutes of Health (NIH).
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-13 05:11
医学,生命科学网